H.C. Wainwright Lowers PT on Soleno (SLNO), Keeps a Buy Rating

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the Best Small-Cap Growth Stocks to Buy According to Hedge Funds. On March 4, H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Soleno Therapeutics, Inc. (NASDAQ:SLNO) from $120 to $100, while maintaining a Buy rating on the shares.

The rating follows the company’s fiscal Q4 2025 earnings reported on February 25. Soleno posted quarterly revenue of $91.73 million, surpassing estimates by $3.18 million. The EPS of $0.8 also topped the consensus by $0.09. The revenue was notable as it accounts for less than nine months of commercial sales from the early commercial adoption of VYKAT XR.

Copyright: dolgachov / 123RF Stock Photo

​The analyst said in a research note that he sees a strong commercial outlook for the company. He expects the company’s VYKAT XR to capture 20% market share in the total Prader-Willi syndrome market. This is backed by 859 active patients on VYKAT XR treatment at the end of Q4 2025, up from 764 in Q3.

​Soleno Therapeutics, Inc. (NASDAQ:SLNO) is a clinical-stage biopharmaceutical company developing novel therapies for rare diseases, including Prader-Willi Syndrome.